middle.news
Nexalis Therapeutics Launches First Human Trial of IRX-616a for Panic Disorder
9:32am on Thursday 19th of March, 2026 AEDT
•
Healthcare
Read Story
Nexalis Therapeutics Launches First Human Trial of IRX-616a for Panic Disorder
9:32am on Thursday 19th of March, 2026 AEDT
Key Points
Phase 1 trial dosing commenced for IRX-616a
First-in-human study targeting panic disorder
Safety Review Committee to assess dose escalation in April
Trial on track to complete dosing by June 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nexalis Therapeutics (ASX:NX1)
OPEN ARTICLE